-

Kirby McInerney LLP Reminds Hims & Hers Health, Inc. (HIMS) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025, through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[LEARN MORE ABOUT THE CLASS ACTION]

On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” under which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.

The lawsuit alleges that Hims & Hers failed to disclose to investors that: (1) the Company was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy that endangered patients; and (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.

If you purchased or otherwise acquired Hims & Hers securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:HIMS

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, V...

CRMT Investors: Contact Kirby McInerney LLP About Investigation into Car-Mart, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Car-Mart, Inc. (“Car-Mart” or the “Company”) (NASDAQ:CRMT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 15, 2025, Car-Mart disclosed it would delay filing its annual report because “management identified the need t...

INSP INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Inspire Medical Systems, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE:INSP) investors of the January 5, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Inspire securities between August 6, 2024 through August 4, 2025 (“the Class Period”). Follow the link below for more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit About? The lawsuit allege...
Back to Newsroom